Evidence map›Paper›PMID 33652630›Full record

ArticleBiology2021

Preparation, Optimization and In-Vitro Evaluation of Curcumin-Loaded Niosome@calcium Alginate Nanocarrier as a New Approach for Breast Cancer Treatment.

Iman Akbarzadeh, Mona Shayan, Mahsa Bourbour, Maryam Moghtaderi, Hassan Noorbazargan, Faten Eshrati Yeganeh, Samaneh Saffar, Mohammadreza Tahriri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 105 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. In-vivo and in-vitro assessment of curcumin loaded bile salt stabilized nanovesicles for oral delivery.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Iman AkbarzadehDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran 145888-9694, Iran.
Mona ShayanCore Facility Center, Pasteur Institute of Iran, Tehran 1316943551, Iran.ORCID 0000-0003-1211-8113
Mahsa BourbourDepartment of Biotechnology, Alzahra University, Tehran 1993893973, Iran.
Maryam MoghtaderiDepartment of Chemical Engineering, Faculty of Engineering, University of Tehran, Tehran 141556619, Iran.
Hassan NoorbazarganDepartment of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran.
Faten Eshrati YeganehDepartment of Chemistry, Science and Research Branch, Islamic Azad University, Tehran 1477893855, Iran.
Samaneh SaffarCore Facility Center, Pasteur Institute of Iran, Tehran 1316943551, Iran.
Mohammadreza TahririDepartment of Engineering, Norfolk state University, Norfolk, VA 23504, USA.
Pasteur Institute of Iran · IRAlzahra University · IRIslamic Azad University, Science and Research Branch · IRNorfolk State University · USShahid Beheshti University of Medical Sciences · IRSharif University of Technology · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the most common causes of mortality, and its various treatment methods can have many challenges for patients. As one of the most widely used cancer treatments, chemotherapy may result in diverse side effects. The lack of targeted drug delivery to tumor tissues can raise the possibility of damage to healthy tissues, with attendant dysfunction. In the present study, an optimum formulation of curcumin-loaded niosomes with a calcium alginate shell (AL-NioC) was developed and optimized by a three-level Box-Behnken design-in terms of dimension and drug loading efficiency. The niosomes were characterized by transmission electron microscopy, Fourier-transform infrared spectroscopy, and dynamic light scattering. The as-formulated niosomes showed excellent stability for up to 1 month at 4 °C. Additionally, the niosomal formulation demonstrated a pH-dependent release; a slow-release profile in physiological pH (7.4), and a more significant release rate at acidic conditions (pH = 3). Cytotoxicity studies showed high compatibility of AL-NioC toward normal MCF10A cells, while significant toxicity was observed in MDA-MB-231 and SKBR3 breast cancer cells. Gene expression studies of the cancer cells showed downregulation of Bcl2, cyclin D, and cyclin E genes, as well as upregulation of P53, Bax, caspase-3, and caspase-9 genes expression following the designed treatment. Flow cytometry studies confirmed a significant enhancement in the apoptosis rate in the presence of AL-NioC in both MDA-MB-231 and SKBR3 cells as compared to other samples. In general, the results of this study demonstrated that-thanks to its biocompatibility toward normal cells-the AL-NioC formulation can efficiently deliver hydrophobic drugs to target cancer cells while reducing side effects.

Indexed as

AnticancerBreast cancerCalcium alginateCurcuminNiosome

Identifiers

PMID33652630
PMCPMC7996962
OpenAlexW3134379131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.